Renalytix Plc (RNLXY)

OTCMKTS · Delayed Price · Currency is USD
0.2010
+0.0010 (0.50%)
Apr 17, 2025, 4:00 PM EDT
Market Cap 35.12M
Revenue (ttm) 2.89M
Net Income (ttm) -28.16M
Shares Out n/a
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,200
Average Volume 34,855
Open 0.2180
Previous Close 0.2000
Day's Range 0.2010 - 0.2180
52-Week Range 0.1200 - 0.8900
Beta n/a
RSI 44.30
Earnings Date Mar 28, 2025

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, pa... [Read more]

Sector Healthcare
Founded 2018
Employees 102
Stock Exchange OTCMKTS
Ticker Symbol RNLXY
Full Company Profile

Financial Performance

In 2024, Renalytix's revenue was $2.29 million, a decrease of -32.74% compared to the previous year's $3.40 million. Losses were -$33.46 million, -26.64% less than in 2023.

Financial Statements

News

Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript

Renalytix Plc (OTC:RNLXY) Q2 2025 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants Julian Baines - Executive Chairman Fergus Fleming - Chief Technology Officer James McCullough...

4 weeks ago - Seeking Alpha

Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025

LONDON and NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...

5 months ago - PRNewsWire